

To the OMX Nordic Exchange Copenhagen  
and the Press

Release number 21/2008

## **Pharmexa and the Novo Nordisk Foundation Center for Protein Research enter into a research collaboration**

*Summary: Pharmexa and the Novo Nordisk Foundation Center for Protein Research (CPR) have entered into a research collaboration agreement to optimize and implement Pharmexa's proprietary protein expression system for high throughput protein production at the CPR to, systematically study human proteins of medical relevance.*

Proteins constitute the machinery of life, carrying out a multitude of vital biological functions. When the human genome was sequenced, more than 20,000 genes were identified that could code for proteins. However, of all these possible proteins, only relatively few have been extensively studied and characterized. As proteins are the targets for >95% of all drugs, a better understanding of what all these different proteins do could lead to breakthrough discoveries in the treatment of many different diseases. This is one of the main goals of the Novo Nordisk Foundation Center for Protein Research (CPR) - which recently was established at the Faculty of Health Sciences, University of Copenhagen - to systematically study protein function in health and disease and to identify new targets for medical intervention.

According to Michael Sundström, Managing Director of the CPR, *"to understand what a protein does, it is often necessary to produce it in sufficient quantities to be studied. We plan to produce and characterize thousands of different proteins, so it is also essential that we can produce them very quickly. We believe that Pharmexa's expression system will be readily adaptable to the fast screening methods used at the CPR and particularly useful for more complex proteins that are not easy to produce using standard methods"*.

Over the past 10 years, Pharmexa has developed a proprietary protein expression system utilizing stable insect cell lines. The system has been successfully used to make high quality proteins for use in research and clinical trials. The purpose of the collaboration is to evaluate and, if necessary, adapt the system for the high throughput screening methods used at the CPR for the evaluation of human proteins of potential medical relevance.

Achim Kaufhold, CEO of Pharmexa says: *"Our scientists have developed a robust and unique expression system that is extremely useful for basic research as well as the industrial production of proteins. The CPR is established to conduct world class research into proteins of significant medical interest. We are very pleased that they have chosen to work with our protein expression system in this important endeavour."*

The collaboration will not materially affect Pharmexa's financial guidance for 2008.

Hørsholm, October 6, 2008

Achim Kaufhold  
Chief Executive Officer

**Additional information:**

Claude Mikkelsen, Senior Vice President, Finance & Investor Relations, tel. +45 4516 2525 or +45 4060 2558

Achim Kaufhold, Chief Executive Officer, tel +45 4516 2525

***For the editors:** Pharmexa A/S is a development stage company in the field of active immunotherapy. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer and chronic diseases, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Collaborative agreements include H. Lundbeck and Bavarian Nordic. With operations in Denmark and USA, Pharmexa employs approximately 40 employees and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX.*